ENTITY

TxCell SA (TXCL FP)

5
Analysis
Health CareFrance
TxCell SA researches and develops biotechnological products. The Company offers cell-based immunotherapies for the treatment of chronic inflammatory, bowel, joint, and neurological diseases.
more
bullishTxCell SA
22 Feb 2018 16:51Issuer-paid

TxCell - Robust and stable Treg manufacturing

TxCell has disclosed that it has a viable manufacturing route for its novel CAR Treg products. This uses a stable but low-frequency Treg cell type....

Share
bullishTxCell SA
09 Oct 2017 23:12Issuer-paid

Humanised CAR Tregs are a key step forward

TxCell has announced it has a promising humanised CAR-Treg product that can be developed to control graft rejection in solid organ transplant. A...

Share
bullishTxCell SA
11 Jul 2017 22:22Issuer-paid

Getting production in order

TxCell has agreed an important manufacturing supply contract with Lentigen, a German-US producer of the critical lentivirus reagent essential for...

Share
bullishTxCell SA
14 Mar 2017 20:10Issuer-paid

Aiming for first CAR Treg

TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform continues to develop well. TxCell has four indications in preclinical development...

Share
bullishTxCell SA
28 Feb 2017 18:33Issuer-paid

Exciting CAR opportunities; multiple indications

TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform is developing well. CAR Tregs offer a powerful and versatile new approach to...

Share
No more insights
x